Vandetanib: IQWiG assessed data subsequently submitted by the manufacturer

Hint of minor added benefit in people aged under 65 years/greater harm in people aged over 65 years

2013-10-01

(Press-News.org) Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. On the inclusion of additional study data subsequently provided by the drug manufacturer in the commenting procedure, the German Institute for Quality and Efficiency in Health Care (IQWiG) came to a different conclusion in an addendum: According to the findings, there is a hint of a minor added benefit in people aged under 65 years, but a hint of greater harm (lesser benefit) in older patients in comparison with standard therapy ("best supportive care").

Additional analyses on pain and side effects

In IQWiG's dossier assessment from June 2013, important data for the harm side were missing. The Institute was therefore unable to balance positive and negative effects, and could therefore not accord an added benefit.

In the commenting procedure conducted by the Federal Joint Committee (G-BA), the pharmaceutical company now submitted additional analyses both on side effects (adverse events) and on the degree of pain. The G-BA subsequently commissioned the Institute to investigate whether, using these additional data, an added benefit of vandetanib is proven with regards to morbidity (symptoms, here: pain) and the uncertainties regarding harm are resolved.

Pain rated as severe or serious

The dossier assessment concluded that pain occurs later or gets worse later in patients aged under 65 years if they are treated with vandetanib. In people aged over 65 years, however, there was no difference in comparison with "best supportive care".

The data provided in the manufacturer's dossier did not allow to rate the severity of the pain. The additional analysis now showed that this pain in patients with this kind of pain progression is to be rated as "severe" or "serious" symptoms. IQWiG therefore considers there to be a hint of an added benefit, the extent of which is to be rated as "considerable" – and not only "minor" as in the dossier assessment from June 2013.

More side effects under vandetanib

The additional analysis on side effects (adverse events) now allowed to assess the data although the patients in the two study arms were treated and observed for different lengths of time. It showed that vandetanib causes side effects more frequently than "best supportive care" – independent from the patients' age. This applies to severe adverse events and skin rash. There was no difference between the study arms regarding serious adverse events and discontinuations of treatment due to side effects. IQWiG rated the extent of harm as "major" (severe adverse events) and "considerable" (skin rash).

People aged under 65 years: negative effects do not outweigh positive effects

IQWiG considers there to be both positive and negative effects in people aged under 65 years: The delay in pain progression is not outweighed by more frequent side effects. But IQWiG downgraded the extent of added benefit from "considerable" to "minor".

The assessment only found negative effects in the group of people aged over 65 years: There is only "major" and "considerable" harm in the form of side effects.

Overall, IQWiG concludes that there is a hint of minor added benefit in patients aged under 65 years, but a hint of lesser benefit in patients aged over 65 years of vandetanib compared with "best supportive care".

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturers' dossiers and the IQWiG dossier assessments, the G-BA conducted commenting procedures, in which the manufacturer submitted additional information. The G-BA subsequently commissioned IQWiG to undertake a new assessment, with the additional data included.

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent the addendum on vandetanib to the contracting agency on 8 August 2013. The G-BA then decides on the extent of the added benefit in each case, thus completing the early benefit assessment.

###

ELSE PRESS RELEASES FROM THIS DATE:

Fertility problems? Joining the 'breakfast club' can help

2013-10-01

Jerusalem, Oct. 1, 2013 -- A new study by researchers at the Hebrew University of Jerusalem and Tel Aviv University reveals that eating a good breakfast can have a positive impact on women with problems of infertility. In recent years, nutritional research has found that our weight is affected not only by the level of calorie intake, but also by the question of when to consume large amounts of calories. Now, research, conducted by Prof. Oren Froy, director of the Nutrigenomics and Functional Foods Research Center at the Robert H. Smith Faculty of Agriculture, Food ...

Body image impacts on weight gain during pregnancy

2013-10-01

How women perceive their bodies during pregnancy and how that impacts on their weight gain has been the subject of a new study by University of Adelaide researchers. Researchers in the University's Robinson Institute and the School of Psychology have studied more than 400 South Australian women to better understand the links between body image and excessive weight gain during pregnancy. The results, published in the journal Women and Birth, show that more than 70% of pregnant women who are overweight or obese under-estimate their weight. Those who under-estimate their ...

Scientists tap into spinal response from gastric reflux

2013-10-01

University of Adelaide researchers have made advances in the understanding of one of the world's most common medical conditions, gastric reflux, and how patients experience pain from it. Gastric reflux affects as many as one in five people in Western countries and is on the increase in Asia. Diet and lifestyle, as well as genetic and hormonal issues, are commonly considered to be major causes of gastric reflux. In laboratory studies, researchers have identified the nerve pathways in the spinal cord that transmit pain signals associated with gastric reflux to the brain. "This ...

CNIC researchers minimize damage during a heart attack with a drug costing less than €2.00

2013-10-01

The study, involving emergency ambulance services and teams at seven hospitals across Spain, shows categorically that this simple, low-cost strategy could easily be extended throughout the world, providing significant clinical benefit. This would change current practice for treating heart-attack patients, who currently receive no medication before undergoing angioplasty surgery, the recommended procedure for removing the arterial blockage that caused the infarction. Borja Ibáñez—joint leading investigator on the study with Valentín Fuster—explains that clinical research ...

Macrophage-derived mediators may have potential as biomarkers for urinary stone risk

2013-10-01

Arnhem, 30 September 2013- A balance between the activation of the inflammatory macrophages and suppression of the anti-inflammatory macrophages in the kidney may play a pivotal role in kidney stone formation. These macrophage-derived mediators may have potential as biomarkers to reflect the urinary stone risk, according to a new study from Japan, which was recently presented at the recent 2nd Meeting of the EAU Section of Urolithiasis and received Clinical Research Award. Compared to that of control subjects, the urine from individuals with a history of kidney stone formation ...

Restricting Voting Rights Act could mean fewer African-Americans on city councils

2013-10-01

Efforts to limit the reach of the Voting Rights Act of 1965 (VRA), the legislation that banned discrimination in voting, could negatively impact black political representation, according to a new study from researchers at Rice University, the University of Wisconsin-Milwaukee and Ohio University. "Are We There Yet? The Voting Rights Act and Black Representation on City Councils, 1981-2006" is one of the first studies to take a "big picture" look at a large sample of city councils over time to see where African-Americans are making gains, where they are adding or losing ...

Variations in death rates after surgery for oesophageal and gastric cancers

2013-10-01

A pilot study has shown large variations between European countries in patient survival after surgery for oesophageal and gastric cancers. The 2013 European Cancer Congress (ECC2013) [1] will hear today (Tuesday) that the reasons for these differences are not clear and cannot be explained simply in terms of the volume of patients treated at each hospital. Numerous previous studies have shown that hospitals that see and treat the highest numbers of patients for a variety of diseases and conditions ranging from cancer to cardiology tend to have greater expertise, resulting ...

Clinician observations of preschoolers' behavior help to predict ADHD at school age

2013-10-01

Don't rely on one source of information about your preschoolers' inattention or hyperactivity. Rather, consider how your child behaves at home as well as information from his or her teacher and a clinician. This advice comes from Sarah O'Neill, of The City College of New York, based on research she conducted at Queens College (CUNY), in an article published in Springer's Journal of Abnormal Child Psychology. The study examines how well parent, teacher, and clinician ratings of preschoolers' behavior are able to predict severity and diagnosis of attention deficit hyperactivity ...

The MGC Herbarium: Information source of plant diversity in the Mediterranean

2013-10-01

To understand the world's biological diversity, the information included in scientific collections is essential. For this reason, many projects have been focused on computerizing the data from these collections and making them openly available to researchers on biodiversity and conservation. The MGC Herbarium of the University of Malaga (Spain) includes 76000 sheets of vascular plants or cormophyta, 73156 of which have been computerized. The data sheets are accessible through the GBIF data portal in the web page http://data.gbif.org/datasets/resource/8105/. The basic ...

New target to fight HIV infection identified

2013-10-01

A mutant of an immune cell protein called ADAP (adhesion and degranulation-promoting adaptor protein) is able to block infection by HIV-1 (human immunodeficiency virus 1), new University of Cambridge research reveals. The researchers, who were funded by the Wellcome Trust, believe that their discovery will lead to new ways of combatting HIV. Professor Chris Rudd from the Department of Pathology, who led the research, said: "One exciting aspect about this new target for HIV intervention is that we should be able to fight HIV without compromising the immune system's ability ...

Vandetanib: IQWiG assessed data subsequently submitted by the manufacturer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: